article thumbnail

CMO Moves: Regulatory Catalysts for Drug Manufacturing-November

Pharmaceutical Technology

However, efficiently manufacturing the drug represents another barrier to cross before realizing the full revenue potential then successfully. Each month, Pharmaceutical Technology takes a look at recent decisions taken by regulatory and reimbursement agencies and identifies the key manufacturing players that can be impacted by them.

article thumbnail

Chinese manufacturers’ transition to innovative pharma requires more investment

Pharmaceutical Technology

Despite China producing a significant proportion of the world’s API supply (mostly small molecule), it manufactures relatively few biosimilar and innovator drugs and no cell and gene therapies for the western markets of Europe and the US despite investments and an increasing number of startups to improve innovative manufacture.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CMO Moves: Regulatory catalysts for drug manufacturing – March 2023

Pharmaceutical Technology

In such turbulent times, ensuring the most efficient and cost-effective manufacturing frameworks becomes even more important. Most pharmaceutical and biotech companies outsource certain production tasks to contract manufacturing organizations (CMOs). Sharp Packaging Services is producing the solid dose of the drug and packaging it.

article thumbnail

Fixed-dose combination: Considerations for design, formulation, manufacturing and analysis

Pharmaceutical Technology

Understanding both the significant competitive advantages that FDC products can offer, and the difficulties and potential pitfalls associated with development and manufacturing of FDC drugs in oral solid dosage forms is a critical first step for companies exploring this approach. Pharmaceutical companies – and the FDA – are embracing FDCs.

article thumbnail

CMO Moves: Regulatory catalysts for therapy manufacturing -January

Pharmaceutical Technology

In order to get a therapy to the market, pharma companies often outsource the drug manufacturing to specialist contract manufacturing organizations (CMOs). While Catalent Inc and PCI Pharma Services are in charge of the solid dose and packaging of Lupkynis, Lonza is manufacturing the small molecule API. EMA and NICE news.

article thumbnail

What are Salt Substitutes and How Can Food Manufacturers Choose the Right One?

XTalks

Last week, the US Food and Drug Administration (FDA) proposed to amend the standards of identity (SOIs) to permit the use of salt substitutes in foods for which salt is a standard ingredient. So, how can manufacturers choose the right salt substitute for food and beverage products? Califf, in a press release.

article thumbnail

What is the Difference Between Biologics and Biosimilars?

Pharma Packaging Solutions

Biologics are drug products that are manufactured using materials from living sources. A biosimilar is a biologic that is similar enough to an existing FDA-approved product that it performs in exactly the same way, but different enough to avoid legal battles with the producers of the original product. What are Biosimilars?